In the randomized , double-blind ACCOAST ( A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction ) trial , 4,033 patients were diagnosed with NSTEMI and 68.7 % underwent PCI ; 1,394 received pre-treatment with prasugrel ( 30-mg loading dose ) , and 1,376 received placebo .